Here’s a first: Regeneron cuts forecast after hard-charging Eylea sales miss

Carly Helfand

Here's something isn't used to: Cutting forecasts for blockbuster eye drug . But that's just what the New York biotech did Tuesday amid lower-than-expected third-quarter results.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS